http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+28++Filed+by%3A+TAYMANS+JILL+M/26575716.html si-local-file:///var/storage/secattach/20260529/26575716.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+28++Filed+by%3A+TAYMANS+JILL+M/26575716.html Fri, 29 May 2026 16:31:00 -0400 CCEL O.00166844 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+28++Filed+by%3A+TAYMANS+JILL+M/26575716.html si-local-file:///var/storage/secattach/20260529/26575716.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+28++Filed+by%3A+TAYMANS+JILL+M/26575716.html Fri, 29 May 2026 16:31:00 -0400 CCEL O.00166844 http://www.streetinsider.com/Corporate+News/Cryo-Cell+receives+NYSE+American+compliance+plan+acceptance/26460790.html <p>Cryo-Cell International Inc. (NYSE American: CCEL) announced that NYSE American has accepted the company's compliance plan to address listing standard deficiencies.</p><p>The cord blood banking company was notified in March that it failed to meet Section 1003(a) of the NYSE American Company Guide due to stockholders' deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years ending November 30, 2023, 2024, and 2025.</p><p>NYSE Regulation reviewed and accepted Cryo-Cell's plan submitted on April 8, 2026, granting a compliance period through September 9, 2027. The company's common stock will continue trading on NYSE American during http://www.streetinsider.com/Corporate+News/Cryo-Cell+receives+NYSE+American+compliance+plan+acceptance/26460790.html Fri, 08 May 2026 16:00:45 -0400 CCEL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+06/26460791.html si-local-file:///var/storage/secattach/20260508/26460791.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+06/26460791.html Fri, 08 May 2026 16:00:00 -0400 CCEL O.00166844 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+06/26460791.html si-local-file:///var/storage/secattach/20260508/26460791.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CRYO+CELL+INTERNATIONAL+++For%3A+May+06/26460791.html Fri, 08 May 2026 16:00:00 -0400 CCEL O.00166844 http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Press+Releases/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- <b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)</b> (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. </p><p> As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its http://www.streetinsider.com/Business+Wire/Cryo-Cell+Receives+Acceptance+of+Compliance+Plan+From+NYSE+American/26460771.html Fri, 08 May 2026 16:00:00 -0400 A.03562356 CCEL O.00064716 O.00166844 http://www.streetinsider.com/Corporate+News/Cryo-Cell+receives+renewed+FACT+accreditation+through+2029/26383423.html <p>Cryo-Cell International Inc. (NYSE American: CCEL) announced it has received renewed Foundation for the Accreditation of Cellular Therapy accreditation for cord blood collection, banking, and release operations. The accreditation extends through April 3, 2029.</p><p>The company first received FACT accreditation in 2014. The renewal confirms Cryo-Cell's compliance with NetCord-FACT Standards for Cord Blood Banking, which the company describes as internationally recognized quality standards in cellular therapy.</p><p>FACT accreditation requires on-site inspection by experts, documentation review, and demonstrated compliance across collection, processing, testing, storage, and release protocols. The standards are used by transplant and cancer centers when selecting cord blood units from public http://www.streetinsider.com/Corporate+News/Cryo-Cell+receives+renewed+FACT+accreditation+through+2029/26383423.html Tue, 28 Apr 2026 16:00:38 -0400 CCEL http://www.streetinsider.com/Hot+Corp.+News/Cryo-Cell+receives+renewed+FACT+accreditation+through+2029/26383423.html <p>Cryo-Cell International Inc. (NYSE American: CCEL) announced it has received renewed Foundation for the Accreditation of Cellular Therapy accreditation for cord blood collection, banking, and release operations. The accreditation extends through April 3, 2029.</p><p>The company first received FACT accreditation in 2014. The renewal confirms Cryo-Cell's compliance with NetCord-FACT Standards for Cord Blood Banking, which the company describes as internationally recognized quality standards in cellular therapy.</p><p>FACT accreditation requires on-site inspection by experts, documentation review, and demonstrated compliance across collection, processing, testing, storage, and release protocols. The standards are used by transplant and cancer centers when selecting cord blood units from public http://www.streetinsider.com/Hot+Corp.+News/Cryo-Cell+receives+renewed+FACT+accreditation+through+2029/26383423.html Tue, 28 Apr 2026 16:00:38 -0400 CCEL http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Press+Releases/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615 http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html <p> OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company’s latest FACT re-accreditation extends for three more years, with the latest renewal effective through April 3, 2029. </p><p> The FACT accreditation was issued after Cryo-Cell International, Inc. demonstrated compliance with the NetCord-FACT Standards for Cord Blood Banking — the most rigorous internationally recognized quality framework in cellular therapy. </p><p> <b>Accreditation http://www.streetinsider.com/Business+Wire/Cryo-Cell+International+Receives+FACT+Re-accreditation%2C+Setting+the+Longest+Independently+Validated+Quality+Track+Record+Among+U.S.+Private+Cord+Blood+Banks/26383411.html Tue, 28 Apr 2026 16:00:00 -0400 A.03562356 A.07097846 CCEL O.00064716 O.00166844 O.31843615